1. The Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses
- Author
-
Giuseppe Ciccone, Maria Luigia Ibba, Gabriele Coppola, Silvia Catuogno, and Carla Lucia Esposito
- Subjects
NSCLC ,aptamer ,ASO ,RNAi ,targeted therapy ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Non-small-cell lung cancer (NSCLC) is the second most diagnosed type of malignancy and the first cause of cancer death worldwide. Despite recent advances, the treatment of choice for NSCLC patients remains to be chemotherapy, often showing very limited effectiveness with the frequent occurrence of drug-resistant phenotype and the lack of selectivity for tumor cells. Therefore, new effective and targeted therapeutics are needed. In this context, short RNA-based therapeutics, including Antisense Oligonucleotides (ASOs), microRNAs (miRNAs), short interfering (siRNA) and aptamers, represent a promising class of molecules. ASOs, miRNAs and siRNAs act by targeting and inhibiting specific mRNAs, thus showing an improved specificity compared to traditional anti-cancer drugs. Nucleic acid aptamers target and inhibit specific cancer-associated proteins, such as “nucleic acid antibodies”. Aptamers are also able of receptor-mediated cell internalization, and therefore, they can be used as carriers of secondary agents giving the possibility of producing very highly specific and effective therapeutics. This review provides an overview of the proposed applications of small RNAs for NSCLC treatment, highlighting their advantageous features and recent advancements in the field.
- Published
- 2023
- Full Text
- View/download PDF